Kardashians, move over. Twitter is a vibrant community where physicians can connect, discuss, and collaborate with global peers.

Preoperative prescriptions and higher doses predicted persistent use 3 to 6 months later, hinting at windows for prevention.

The study is unique in its size, scope, and ability to assess effects on hard clinical endpoints, an expert says.

The biomarker-based approach identified high-risk ACS patients and can lead to greater precision in their care, says one expert.

Big topics and big trials dominate this year’s ESC Congress, partnering with the World Heart Federation for a “global focus.”

No products are being pulled from the market; instead, users are told to deploy the valve using slow and continuous pressures.

Despite being a negative trial, a RELAX-AHF-2 co-investigator maintains there is value in pursuing this type of therapy.

Viability testing continues to have a role as one factor of many that go into the decision to take a patient in for bypass surgery.

Anticoagulants play an important role, too, but antiplatelet therapy can’t be omitted, the lead researcher says.

The new scientific advisory zeros in on triglyceride effects and on newer prescription-strength products, as studied in REDUCE-IT.

Randomized clinical trials are lacking in valve surgery—one surgeon’s series may be the “best estimate of what’s possible.”